LIXTE Biotechnology Reports Promising Interim Ovarian Cancer Trial Results at SGO Conference

LIXTE Biotechnology Holdings Inc. announced preliminary results from its clinical trial evaluating the proprietary compound LB-100 in combination with dostarlimab at the 2026 Society of Gynecologic Oncology conference. Interim data from 20 evaluable patients demonstrated a 40% disease control rate with encouraging survival trends and an acceptable safety profile, supporting continued enrollment of an expanded cohort.

The company is investigating the combination’s potential to enhance immunotherapy response in ovarian clear cell carcinoma, a challenging cancer subtype. LIXTE has demonstrated that LB-100, its first-in-class PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance immunotherapies and improve outcomes for cancer patients.

This research represents part of a pioneering effort in an entirely new field of cancer biology called activation lethality, which is advancing a new treatment paradigm. LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma. Additional information about the company’s work can be found at https://www.lixte.com.

Through its wholly owned subsidiary, Liora Technologies Europe Ltd., LIXTE is also developing electronically controlled proton therapy systems for treating tumors in various cancer types. Liora’s proprietary flagship technology, the LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. More details about this technology are available at https://www.lioratechnologies.com.

The interim results are significant because they provide early clinical validation for a novel approach to overcoming immunotherapy resistance in ovarian cancer. The 40% disease control rate in this difficult-to-treat population suggests that LB-100 may help make immunotherapies more effective for patients who typically respond poorly to current treatments. The acceptable safety profile reported supports further investigation of this combination therapy approach.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is LIXTE Biotechnology Reports Promising Interim Ovarian Cancer Trial Results at SGO Conference.

The post LIXTE Biotechnology Reports Promising Interim Ovarian Cancer Trial Results at SGO Conference appeared first on citybuzz.